首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1624381

2024 年至 2031 年下游加工市場規模（依最終用戶、業務規模、生物分子類型和地區劃分）

Downstream Processing Market Size By Final User (Biopharmaceutical Companies, Contract Manufacturing Organisations, Academic Labs, and Research Institutes), Operational Scale, Biomolecule Type, & Region for 2024-2031

出版日期: 2024年10月30日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年至 2031 年下游加工市場評估

受生物製藥需求增加、慢性病發病率上升以及一次性技術日益普及等因素推動，下游加工市場預計將在未來幾年大幅增長。據 Verified Market Research 分析師稱，下游加工市場規模預計將從 2024 年的 299.3 億美元增至 2024 年的 1,001.8 億美元。

企業不斷創新，提高效率和可擴展性，確保市場活力和競爭力。這將使市場從 2024 年到 2031 年的複合年增長率達到 16.30%。

下游加工市場定義/概述

下游加工是指生物製品生產後的重要步驟。這涉及從最初發現的複雜混合物中分離和純化所需產品。這種混合物通常稱為發酵液，可能含有細胞、廢棄蛋白質、營養素和其他細胞產品。

下游加工對於從生物來源獲取有價值的產品起著關鍵作用。它們用於純化胰島素和疫苗等生物製藥、分離食品生產等工業過程所需的酵素以及從植物和微生物中提取藥用天然產物。本質上，我們從細胞和生物體中提取原始輸出物，並將其轉化為純淨的功能性產品，以用於我們的健康和各種工業應用。

哪些因素推動下游加工廠需求激增？

生物製藥（一種源自生物體或其細胞過程的藥物）的需求不斷增長，是下游加工的主要驅動力。生物製藥比傳統藥物有幾個優勢，包括目標特異性高、副作用少、能夠治療複雜疾病。這促使了生物製藥的開發和生產的激增，例如胰島素、用於癌症治療的單株抗體和基因治療藥物。因此，對高效、可擴展的下游加工技術來純化和分離這些複雜分子的需求龐大。

此外，癌症、糖尿病和自體免疫疾病等慢性病的增加給全球醫療保健系統帶來了巨大壓力。這些慢性疾病通常需要長期治療，而生物製藥被證明是這場鬥爭中的強大武器。例如，生物製藥可以透過調節血糖水平來幫助控製糖尿病，或比傳統化療藥物更精確地瞄準癌細胞，最大限度地減少患者的副作用。隨著全球人口不斷老化以及慢性病發病率不斷上升，對有效生物製藥療法的需求可能會相應增加，從而推動下游加工市場的發展。

哪些因素阻礙了下游加工市場的成長？

下游處理可能是一個非常昂貴的工作。特別是色譜系統和超濾設備需要大量的資本支出。此外，色譜樹脂和過濾器等消耗品也會增加成本。此外，熟練的勞動力對於操作和維護下游加工設備以及確保製程效率至關重要。由於需要專業知識，很難獲得合格的人員，而且他們的薪資對生產成本有很大影響。

此外，下游加工本質上很複雜，涉及針對要純化的特定產品定制的多個步驟。必須仔細優化每個步驟以實現高產量並滿足嚴格的純度要求。這個優化過程非常耗時，並且需要色譜、過濾和蛋白質生物化學等領域的專業知識。下游加工的複雜性可能對中小型公司和首次進入生物製藥製造領域的公司構成重大課題。我們可能沒有內部專業知識或資源來開發和實施高效的精煉流程，這可能會阻礙我們在市場上有效競爭。

The downstream processing market is expected to grow significantly in the coming years, driven by factors such as the increasing demand for biopharmaceuticals, the rising prevalence of chronic diseases, and the growing adoption of single-use technologies. According to the analyst from Verified Market Research, the downstream processing market is estimated to reach a valuation of 100.18 USD Billion over the forecast subjugating around 29.93 USD Billion valued in 2024.

Companies are continually innovating to improve efficiency and scalability, ensuring the market's dynamic and competitiveness. It enables the market to grow at aCAGR of 16.30% from 2024 to 2031.

Downstream Processing Market: Definition/ Overview

Downstream processing refers to the crucial steps taken after a biological product has been produced, typically through fermentation or cell culture. It's all about isolating and purifying the desired product from the complex mixture it's initially found in. This mixture, often called fermentation broth, can contain cells, unwanted proteins, nutrients, and other cellular byproducts.

Downstream processing plays a critical role in obtaining valuable products from biological sources. It's used to purify biopharmaceuticals like insulin and vaccines, isolate enzymes needed for industrial processes like food production, and extract natural products with medicinal properties from plants and microorganisms. In essence, it takes the raw output from cells or organisms and transforms it into the pure and functional products we rely on for health and various industrial applications.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What are the Factors that Surge the Demand for the Downstream Processing Market?

The rising demand for biopharmaceuticals, a category of drugs that are derived from living organisms or their cellular processes, is a major driver for downstream processing. Biopharmaceuticals offer several advantages over traditional medications, including higher target specificity, fewer side effects, and the ability to treat complex diseases. This has led to a surge in the development and production of biopharmaceuticals, such as insulin, monoclonal antibodies for cancer treatment, and gene therapies. As a result, the demand for efficient and scalable downstream processing techniques to purify and isolate these complex molecules has grown significantly.

Furthermore, the increasing prevalence of chronic diseases like cancer, diabetes, and autoimmune disorders places a significant burden on healthcare systems worldwide. These chronic conditions often require long-term treatment, and biopharmaceuticals are proving to be a valuable weapon in this fight. For instance, biopharmaceuticals can help manage diabetes by regulating blood sugar levels or target cancer cells more precisely than traditional chemotherapy drugs, minimizing side effects for patients. As the global population ages and the incidence of chronic diseases continues to rise, the demand for effective biopharmaceutical treatments will correspondingly increase, propelling the downstream processing market forward.

What Factors Hinder the Growth of the Downstream Processing Market?

Downstream processing can be a very expensive endeavor. The cost of equipment can be significant, especially for chromatography systems and ultrafiltration units. Consumables, such as chromatography resins and filters, also add to the bottom line. Furthermore, skilled labor is essential for operating and maintaining downstream processing equipment and ensuring process efficiency. The specialization required can make it challenging to find qualified personnel, and their salaries can contribute significantly to production costs.

Furthermore, Downstream processing is inherently complex, involving a multitude of steps tailored to the specific product being purified. Each step needs to be carefully optimized to achieve high yields and meet stringent purity requirements. This optimization process can be time-consuming and requires specialized expertise in areas like chromatography, filtration, and protein biochemistry. The complexity of downstream processing can pose significant challenges for smaller companies or those venturing into biopharmaceutical production for the first time. They may lack the in-house expertise or resources to develop and implement efficient purification processes, hindering their ability to compete effectively in the market.

Category-Wise Acumens

How Does the Increasing Demand for Biopharmaceutical Companies Contribute the Market Growth?

According to VMR analysis, the biopharmaceutical companies segment is estimated to hold the largest market share during the forecast period. Biopharmaceutical companies are the primary producers of drugs, vaccines, and other biopharmaceuticals. They require robust downstream processing capabilities to handle large-scale production volumes and ensure consistent product quality. Academic labs and research institutes typically work with smaller quantities for research purposes and may not require such extensive downstream processing infrastructure.

Furthermore, Biopharmaceutical companies are constantly striving to improve downstream processing efficiency and scalability. This is crucial for keeping production costs down and meeting growing market demands. Contract Manufacturing Organizations (CMOs), while offering downstream processing services, cater to a wider range of clients with varying needs. Biopharmaceutical companies often have the resources to invest in advanced, scalable downstream processing technologies, giving them an edge.

How does large-scale downstream processing Propel the Growth of the Downstream Processing Market?

The large-scale downstream processing segment is estimated to dominate the Downstream Processing market during the forecast period driven by the surge in demand for biopharmaceuticals, particularly for established drugs and therapies, which necessitates large-scale production to meet market needs. Large-scale downstream processing allows biopharmaceutical companies to achieve higher production volumes efficiently.

Furthermore, Large-scale operations benefit from economies of scale in several ways. Bulk purchasing of raw materials and consumables for downstream processing can lead to lower costs per unit. Additionally, large-scale facilities can potentially streamline processes and optimize resource utilization, further enhancing efficiency. For example, a large-scale facility might implement automated equipment and continuous processing techniques, which can reduce labor costs and improve throughput compared to smaller-scale batch processing. large facilities can leverage their buying power to negotiate better deals with suppliers of chromatography resins, filters, and other essential materials.

Country/Region-wise Acumens

How does Heightened Awareness of the Downstream Processing market Influence Growth in North America?

According to VMR analysts, North America is estimated to dominate the Downstream Processing market during the forecast period. North America boasts a well-established and strong pharmaceutical and biopharmaceutical industry. This translates to a high demand for downstream processing capabilities to support the production of various biopharmaceuticals.

North America has a well-developed healthcare infrastructure with stringent regulatory frameworks for biopharmaceutical production. This focus on quality necessitates advanced downstream processing methods to ensure product safety and efficacy.

Furthermore, Governments in North America, recognizing the potential of biopharmaceuticals to improve public health and drive economic growth, often provide significant funding and support for research and development in biopharmaceutical technologies. This financial backing fuels innovation in downstream processing techniques, encouraging the development of more efficient, scalable, and cost-effective methods for purifying biopharmaceuticals. Additionally, government grants and tax incentives can stimulate private sector investment in R&D, further accelerating advancements in downstream processing technologies. This strong focus on research fosters a collaborative environment where universities, research institutions, and biopharmaceutical companies can work together to develop next-generation downstream processing solutions.

What Factors Contribute to the Potential Opportunities in the Asia Pacific Region?

The Asia Pacific region is estimated to exhibit the highest growth within the Downstream Processing Market during the forecast period. The Asia-Pacific region is home to a vast and growing patient population. This, coupled with a rising middle class with more disposable income for healthcare, creates a significant market for biopharmaceuticals. This translates to a need for expanded downstream processing facilities to meet the anticipated demand. Additionally, As economies in the region flourish, governments are investing heavily in healthcare infrastructure and biopharmaceutical research. This surge in activity creates a strong demand for downstream processing capabilities to support large-scale biopharmaceutical production.

Furthermore, There's a growing emphasis on research and development (R&D) in the Asia-Pacific biopharmaceutical sector. This focus on innovation fosters collaboration between universities, research institutions, and biopharmaceutical companies. This collaborative environment can accelerate advancements in downstream processing technologies, leading to the development of more efficient, scalable, and cost-effective purification methods. Additionally, Regulatory frameworks for biopharmaceutical production in the Asia-Pacific region are becoming more streamlined and harmonized. This can ease the process for companies looking to establish downstream processing facilities in the region.

Competitive Landscape

The downstream processing market is a competitive landscape characterized by a dynamic interplay between established industry leaders and emerging companies with innovative technologies. Well-entrenched players leverage their vast experience, extensive product portfolios, and global reach to maintain a strong market presence.

Some of the prominent players operating in the Downstream Processing Market include:

Lonza Group

Thermo Fisher Scientific Inc.

Danaher Corporation (Pall Corporation)

Sartorius Stedim Biotech S.A.

Merck KGaA (Merck Millipore)

3M Company

Eppendorf AG

GE Healthcare

Bio-Rad Laboratories, Inc.

Boehringer Ingelheim

Latest Developments

In December 2024, Lonza Group partnered with a leading biotechnology company to develop and manufacture a novel gene therapy for a rare genetic disorder. Lonza's expertise in downstream processing will be crucial in purifying and isolating the large quantities of viral vectors needed for this gene therapy treatment. This collaboration highlights the growing importance of downstream processing in bringing innovative biopharmaceutical therapies to patients

In 2024, Thermo Fisher Scientific launched a new chromatography resin specifically designed for high-throughput protein purification. This innovative resin boasts a unique ligand chemistry that offers superior binding capacity and faster purification times for a wide range of protein targets. This can significantly improve the efficiency of downstream processing workflows, especially for biopharmaceutical companies working on large-scale production of protein-based drugs or therapeutics. The new resin is also designed to be compatible with high-flow chromatography systems, further accelerating protein purification processes.

In 2024, Danaher Corporation (Pall Corporation) introduced a new generation of single-use filters for improved performance and scalability in downstream processing.